Thelansis

Neurotrophic Keratitis (NK) Market Outlook Thelansis’s “Neurotrophic Keratitis (NK) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neurotrophic Keratitis (NK) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the mar...

Neurotrophic keratitis (NK) is a degenerative corneal disease caused by trigeminal nerve (cranial nerve V) damage, resulting in corneal sensation loss and breakdown of the corneal epithelium. Corneal healing is also hampered in NK, so superficial corneal damage may progress to an actual epithelial defect, followed by corneal ulceration, stromal melting, and perforation. NK treatment aims to restore corneal integrity and prevent the disease from progressing. The cornea, lacrimal glands, conjunctiva, and eyelids are innervated by sensory branches of the ophthalmic division of the trigeminal nerve. The corneal epithelial cells mutually support the corneal nerves by releasing neurotrophic factors that promote neuronal extension and survival. The corneal nerves initiate two protective reflexes, blinking and tear secretion, responding to adverse stimuli. The nerves also support ocular surface health by releasing a host of trophic neuromediators, including substance P and calcitonin gene-rela...